Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
Joanna Gotfrit(Ottawa Hospital), Michael M. Vickers(Ottawa Hospital), Rakesh Goel(Ottawa Hospital), Mario J. Valdés(Grand River Hospital), Rachel Goodwin(University of Ottawa), Wissam Saliba(Cape Breton University), Patrick H. McCrea(Queen Elizabeth II Health Sciences Centre), Vimoj Nair(Ottawa Hospital), Mark Doherty(Sunnybrook Health Science Centre), Michael P. Thirlwell(McGill University Health Centre), Jessica Corbett(Cancer Care Nova Scotia), Muhammad Haseeb Raza(Muhammad Nawaz Shareef University of Agriculture), Jeff Craswell(Health PEI), Stephen Welch(Cancer Care Ontario), Satareh Samimi(Hôpital du Sacré-Cœur de Montréal), Rami Nassabein(Centre Hospitalier de l’Université de Montréal), Luisa Galvis(Dr. Everett Chalmers Regional Hospital), Stephanie Snow(Dalhousie University), Alwin Jeyakumar(Queen Elizabeth II Health Sciences Centre), Michael Lock(London Health Sciences Centre), Ravi Ramjeesingh(Queen Elizabeth II Health Sciences Centre), Carolyn Nessim(University of Ottawa), Thierry Alcindor(McGill University), Derek J. Jonker(University of Ottawa), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), Angela Hyde(Ottawa Hospital), Erin Kennedy(Mount Sinai Hospital), Donna Fleming(Memorial University of Newfoundland), Scott Berry, Margot J. Burnell(Saint John Regional Hospital), Ronald L. Burkes(Mount Sinai Hospital), Simron Singh(Sunnybrook Health Science Centre), Bruce Colwell, Timothy R. Asmis(Ottawa Hospital), Aamer Mahmud(Queen's University), Colin B. Brown(Cancer Care Nova Scotia), Dominick Bossé(Dana-Farber Cancer Institute), Mohammed Harb(Moncton Hospital), Nathalie Daaboul(Hôpital Charles-Le Moyne)
Cited by 6
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k